<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <meta name="author" content="hbaolong@vip.qq.com" />
  <title>癌症传EN:Thirteen Mountains</title>
  <style>
    html {
      color: #1a1a1a;
      background-color: #fdfdfd;
    }
    body {
      margin: 0 auto;
      max-width: 36em;
      padding-left: 50px;
      padding-right: 50px;
      padding-top: 50px;
      padding-bottom: 50px;
      hyphens: auto;
      overflow-wrap: break-word;
      text-rendering: optimizeLegibility;
      font-kerning: normal;
    }
    @media (max-width: 600px) {
      body {
        font-size: 0.9em;
        padding: 12px;
      }
      h1 {
        font-size: 1.8em;
      }
    }
    @media print {
      html {
        background-color: white;
      }
      body {
        background-color: transparent;
        color: black;
        font-size: 12pt;
      }
      p, h2, h3 {
        orphans: 3;
        widows: 3;
      }
      h2, h3, h4 {
        page-break-after: avoid;
      }
    }
    p {
      margin: 1em 0;
    }
    a {
      color: #1a1a1a;
    }
    a:visited {
      color: #1a1a1a;
    }
    img {
      max-width: 100%;
    }
    svg {
      height: auto;
      max-width: 100%;
    }
    h1, h2, h3, h4, h5, h6 {
      margin-top: 1.4em;
    }
    h5, h6 {
      font-size: 1em;
      font-style: italic;
    }
    h6 {
      font-weight: normal;
    }
    ol, ul {
      padding-left: 1.7em;
      margin-top: 1em;
    }
    li > ol, li > ul {
      margin-top: 0;
    }
    blockquote {
      margin: 1em 0 1em 1.7em;
      padding-left: 1em;
      border-left: 2px solid #e6e6e6;
      color: #606060;
    }
    code {
      font-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;
      font-size: 85%;
      margin: 0;
      hyphens: manual;
    }
    pre {
      margin: 1em 0;
      overflow: auto;
    }
    pre code {
      padding: 0;
      overflow: visible;
      overflow-wrap: normal;
    }
    .sourceCode {
     background-color: transparent;
     overflow: visible;
    }
    hr {
      background-color: #1a1a1a;
      border: none;
      height: 1px;
      margin: 1em 0;
    }
    table {
      margin: 1em 0;
      border-collapse: collapse;
      width: 100%;
      overflow-x: auto;
      display: block;
      font-variant-numeric: lining-nums tabular-nums;
    }
    table caption {
      margin-bottom: 0.75em;
    }
    tbody {
      margin-top: 0.5em;
      border-top: 1px solid #1a1a1a;
      border-bottom: 1px solid #1a1a1a;
    }
    th {
      border-top: 1px solid #1a1a1a;
      padding: 0.25em 0.5em 0.25em 0.5em;
    }
    td {
      padding: 0.125em 0.5em 0.25em 0.5em;
    }
    header {
      margin-bottom: 4em;
      text-align: center;
    }
    #TOC li {
      list-style: none;
    }
    #TOC ul {
      padding-left: 1.3em;
    }
    #TOC > ul {
      padding-left: 0;
    }
    #TOC a:not(:hover) {
      text-decoration: none;
    }
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">癌症传EN:Thirteen Mountains</h1>
<p class="author">hbaolong@vip.qq.com</p>
</header>
<center>
<a href="/3place/azzen">返回首页</a> <a
href="/3place/azzen/mingju.html">本书名句</a> <a
href="/3place/azzen/memo.html">本书注解</a> <a
href="/3place/azzen/index_rich.html">丰富目录</a> <a
href="/3place/azzen/index_readcal.html">同读日历</a> <a
href="/3place/azzen/index_timeline.html">时间线</a> <a
href="/3place/azzen/index_books.html">引用书籍</a> <a
href="/3place/azzen/index_words.html">使用字频</a>
<div id="wx_pic" style="margin:0 auto;display:none;">
<img src='/img/logo.png'/>
</div>
</center>
<h4 id="thirteen-mountains">Thirteen Mountains</h4>
<p>448 “Every sickness is a musical problem”: W. H. Auden, “The Art of
Healing (In Memoriam David Protetch, M.D.),” New Yorker, September 27,
1969.</p>
<p>448 The revolution in cancer research: Bert Vogelstein and Kenneth
Kinzler, “Cancer Genes and the Pathways They Control,” Nature Medicine
10, no. 8 (2004): 789–99.</p>
<p>449 “The purpose of my book”: Susan Sontag, Illness as Metaphor and
AIDS and Its Metaphors (New York: Picador, 1990), 102.</p>
<p>450 The Human Genome Project: “Once Again, Scientists Say Human
Genome Is Complete,” New York Times, April 15, 2003.</p>
<p>450 the Cancer Genome Atlas: “New Genome Project to Focus on Genetic
Links in Cancer,” New York Times, December 14, 2005.</p>
<p>450 “When applied to the 50 most common”: “Mapping the Cancer
Genome,” Scientific American, March 2007.</p>
<p>450 In 2006, the Vogelstein team revealed: Tobias Sjöblom et al.,
“The Consensus Coding Sequences of Human Breast and Colorectal Cancers,”
Science 314, no. 5797 (2006): 268–74.</p>
<p>450 In 2008, both Vogelstein’s group and the Cancer Genome Atlas:
Roger McLendon et al., “Comprehensive Genomic Characterization Defines
Human Glioblastoma Genes and Core Pathways,” Nature 455, no. 7216
(2008): 1061–68. Also see D. Williams Parsons et al., “An Integrated
Genomic Analysis of Human Glioblastoma Multiforme,” Science 321, no.
5897 (2008): 1807–12; and Roger McLendon et al., “Comprehensive Genomic
Characterization.”</p>
<p>452 Only a few cancers are notable exceptions: C. G. Mullighan et
al., “Genome-Wide Analysis of Genetic Alterations in Acute Lymphoblastic
Leukemia,” Nature 446, no. 7137 (2007): 758–64.</p>
<p>452 “In the end,” as Vogelstein put it: Bert Vogelstein, comments on
lecture at Massachusetts General Hospital, 2009; also see Vogelstein and
Kinzler, “Cancer Genes and the Pathways They Control.”</p>
<p>453 Other mutations are not passive players: The distinction between
passenger and driver mutations has generated an enormous debate in
cancer genetics. Many scientists suspect that the initial analysis of
the breast cancer genome may have overestimated the number of driver
mutations. Currently, this remains an open question in cancer genetics.
See, for instance, Getz et al., Rubin et al., and Forrest et al.,
Science 317, no 5844: 1500, comments on Sjöblom article above.</p>
<p>453 In a recent series of studies, Vogelstein’s team: See, for
example, Rebecca J. Leary, “Integrated Analysis of Homozygous Deletions,
Focal Amplifications, and Sequence Alterations in Breast and Colorectal
Cancers,” Proceedings of the National Academy of Sciences of the United
States of America 105, no. 42 (2008): 16224–29; Siân Jones et al., “Core
Signaling Pathways in Human Pancreatic Cancer Revealed by Global Genomic
Analyses,” Science 321, no. 5897 (2008): 1801–6.</p>
<p>454 “Cancer,” as one scientist recently put it: Emmanuel Petricoin,
quoted in Dan Jones, “Pathways to Cancer Therapy,” Nature Reviews Drug
Discovery 7 (2008): 875–76.</p>
<p>455 In a piece published in the New York Times: “To Fight Cancer,
Know the Enemy,” New York Times, August 5, 2009.</p>
<p>456 In 2000, the so-called Million Women Study: Valerie Beral et al.,
“Breast Cancer and Hormone-Replacement Therapy in the Million Women
Study,” Lancet 362, no. 9382 (2003): 419–27.</p>
<p>456 The second controversy also has its antecedents: See, for
instance, F. J. Roe and M. C. Lancaster et al., “Natural, Metallic and
Other Substances, as Carcinogens,” British Medical Bulletin 20 (1964):
127–33; and Jan Dich et al., “Pesticides and Cancer,” Cancer Causes
andandandand Control 8, no. 3 (1997): 420–43.</p>
<p>457 In 2005, the Harvard epidemiologist David Hunter: Yen-Ching Chen
and David J. Hunter, “Molecular Epidemiology of Cancer,” CA: A Cancer
Journal for Clinicians 55 (2005): 45–54.</p>
<p>457 In the mid-1990s, building on the prior decade’s advances: Yoshio
Miki et al., “A Strong Candidate for the Breast and Ovarian Cancer
Susceptibility Gene BRCA1,” Science 266, no. 5182 (1994): 66–71; R.
Wooster et al., “Localization of a Breast Cancer Susceptibility Gene,
BRCA2, to Chromosome 13q12–13,” Science 265, no. 5181 (1994): 2088–90;
J. M. Hall et al., “Linkage of Early-Onset Familial Breast Cancer to
Chromosome 17q21,” Science 250, no. 4988 (1990): 1684–89; Michael R.
Stratton et al., “Familial Male Breast Cancer Is Not Linked to the BRCA1
Locus on Chromosome 17q,” Nature Genetics 7, no. 1 (1994): 103–7.</p>
<p>457 An Israeli woman: Breast cancer patient O. B-L. (name withheld),
interview with author, December 2008.</p>
<p>458 In the mid-1990s, John Dick: Tsvee Lapidot et al., “A Cell
Initiating Human Acute Myeloid Leukaemia After Transplantation into SCID
Mice,” Nature 367, no. 6464 (1994): 645–58.</p>
<p>459 Indeed, as the fraction of those affected by cancer creeps: “One
in three” is from the recent evaluation by the National Cancer
Institute. See
http://www.cancer.gov/newscenter/tip-sheet-cancer-health-disparities.
The number “one in two” comes from the NCI seer statistics,
http://seer.cancer.gov/statfacts/html/all.html, but includes all cancer
sites, summarized in Matthew Hayat et al., “Cancer Statistics, Trends
and Multiple Primary Cancer Analyses,” Oncologist 12 (2007): 20–37.</p>
<p>ATOSSA’S WAR</p>
<p>461 We aged a hundred years: Anna Akhmatova, “In Memoriam, July 19,
1914,” in The Complete Poems of Anna Akhmatova, vol. 1 (Chicago: Zephyr
Press, 1990), 449.</p>
<p>461 It is time, it is time for me too to depart: Aleksandr
Solzhenitsyn, Cancer Ward (New York: Farrar, Straus and Giroux, 1974),
476.</p>
<p>461 On May 17, 1973: “A Memorial Tribute in Honor of Dr. Sidney
Farber, 1903–1973,” Thursday, May 17, 1973. Gift of Thomas Farber to the
author.</p>
<p>464 It is impossible to enumerate: Atossa’s case and her survival
numbers are speculative, but based on several sources. See, for
instance, “Effects of chemotherapy and hormonal therapy for early breast
cancer on recurrence and 15-year survival: An overview of the randomised
trials,” Lancet, 365, no. 9472: 1687–1717.</p>
<p>465 In 1997, the NCI director, Richard Klausner: See Barnett S.
Kramer and Richard D. Klausner, “Grappling with Cancer—Defeatism Versus
the Reality of Progress,” New England Journal of Medicine 337, no. 13
(1997): 931–35.</p>
<p>467 The new drug was none other than Gleevec: See, for example, H.
Joensuu, “Treatment of Inoperable Gastrointestinal Stromal Tumors (GIST)
with Imatinib (Glivec, Gleevec),” Medizinische Klinik (Munich) 97,
suppl. 1 (2002): 28–30; M. V. Chandu de Silva and Robin Reid,
“Gastrointestinal Stromal Tumors (GIST): C-kit Mutations, CD117
Expression, Differential Diagnosis and Targeted Cancer Therapy with
Imatinib,” Pathology Oncology Research 9, no. 1 (2003): 13–19.</p>
<h6 id="阅读日期-2026年02月12日-2026年02月12日-共-1-天">阅读日期：
2026年02月12日-2026年02月12日 共： 1 天</h6>
<script src="https://giscus.app/client.js"
        data-repo="hbaolong/hbaolong.github.io"
        data-repo-id="R_kgDOLetDQg"
        data-category="General"
        data-category-id="DIC_kwDOLetDQs4CfLEl"
        data-mapping="url"
        data-strict="0"
        data-reactions-enabled="1"
        data-emit-metadata="1"
        data-input-position="top"
        data-theme="preferred_color_scheme"
        data-lang="zh-CN"
        crossorigin="anonymous"
        async>
</script>
</body>
</html>
